The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Economic evaluation of human papillomavirus vaccination in the United Kingdom
Open accessAbstract
OBJECTIVE: To assess the cost effectiveness of routine vaccination of 12 year old schoolgirls against human papillomavirus infection in the United Kingdom. DESIGN: Economic evaluation. SETTING: UK. Population Schoolgirls aged 12 or older. MAIN OUTCOME MEASURES: Costs, quality adjusted life years (QALYs), and incremental cost effectiveness ratios for a range of vaccination options. RESULTS: Vaccinating 12 year old schoolgirls with a quadrivalent vaccine at 80% coverage is likely to be cost effective at a willingness to pay threshold of pound30,000 (euro37,700; $59,163) per QALY gained, if the average duration of protection from the vaccine is more than 10 years. Implementing a catch-up campaign of girls up to age 18 is likely to be cost effective. Vaccination of boys is unlikely to be cost effective. A bivalent vaccine with the same efficacy against human papillomavirus types 16 and 18 costing pound13- pound21 less per dose (depending on the duration of vaccine protection) may be as cost effective as the quadrivalent vaccine although less effective as it does not prevent anogenital warts. CONCLUSIONS: Routine vaccination of 12 year old schoolgirls combined with an initial catch-up campaign up to age 18 is likely to be cost effective in the UK. The results are robust to uncertainty in many parameters and processes. A key influential variable is the duration of vaccine protection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiologic classification of human papillomavirus types associated with cervical cancer
Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021641 · Cited by 6,249
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa061741 · Cited by 2,055
Paavonen, J., Jenkins, D., Bosch, F. X., Naud, P., Salmerón, J., Wheeler, C. M., Chow, S.-N., Apter, D. L., Kitchener, H. C., Castellsague, X., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60946-5 · Cited by 1,315
Social Stratification in Science
Cole, J. R., Cole, S., & deB. Beaver, D. (1974) · American Journal of Physics · doi:10.1119/1.1987897 · Cited by 1,135
Nanda, K., McCrory, D. C., Myers, E. R., Bastian, L. A., Hasselblad, V., Hickey, J. D., & Matchar, D. B. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-10-200005160-00009 · Cited by 1,089
The cervical cancer epidemic that screening has prevented in the UK
Peto, J., Gilham, C., Fletcher, O., & Matthews, F. E. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16674-9 · Cited by 808
Villa, L. L., Costa, R. L. R., Petta, C. A., Andrade, R. P., Paavonen, J., Iversen, O.-E., Olsson, S.-E., Høye, J., Steinwall, M., Riis-Johannessen, G., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603469 · Cited by 806
Collaboration in an invisible college.
De Solla Price, D. J., & Beaver, D. (1966) · American Psychologist · doi:10.1037/h0024051 · Cited by 782
Devlin, N., & Parkin, D. (2004) · Health Economics · doi:10.1002/hec.864 · Cited by 709
Joura, E. A., Leodolter, S., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Koutsky, L. A., Garland, S. M., Harper, D. M., Tang, G. W., Ferris, D. G., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60777-6 · Cited by 581
Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
Goldie, S. J., Kohli, M., Grima, D., Weinstein, M. C., Wright, T. C., Bosch, F. X., & Franco, E. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh104 · Cited by 539
Model for Assessing Human Papillomavirus Vaccination Strategies
Elbasha, E. H., Dasbach, E. J., & Insinga, R. P. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1301.060438 · Cited by 491
Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs
Kulasingam, S. L. (2003) · JAMA · doi:10.1001/jama.290.6.781 · Cited by 337
Wiggins, M., Oakley, A., Roberts, I., Turner, H., Rajan, L., Austerberry, H., Mujica, R., & Mugford, M. (2004) · Health Technology Assessment · doi:10.3310/hta8320 · Cited by 296
The effect of use and access on citations
Kurtz, M. J., Eichhorn, G., Accomazzi, A., Grant, C., Demleitner, M., Henneken, E., & Murray, S. S. (2005) · Information Processing & Management · doi:10.1016/j.ipm.2005.03.010 · Cited by 232
Brabin, L., Roberts, S. A., Stretch, R., Baxter, D., Chambers, G., Kitchener, H., & McCann, R. (2008) · BMJ · doi:10.1136/bmj.39541.534109.be · Cited by 209
HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial
on behalf of the ARTISTIC Trial Study Group, Kitchener, H. C., Almonte, M., Wheeler, P., Desai, M., Gilham, C., Bailey, A., Sargent, A., & Peto, J. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603210 · Cited by 204
Trends in cervical cancer survival in Europe, 1983–1994: A population-based study
Bielska‐Lasota, M., Inghelmann, R., van de Poll-Franse, L. V., & Capocaccia, R. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.01.048 · Cited by 191
Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites.
Carter, J. J., Madeleine, M. M., Shera, K. A., Schwartz, S. M., Cushing‐Haugen, K. L., Wipf, G. C., Porter, P. L., Daling, J. R., McDougall, J. K., & Galloway, D. A. (2001) · PubMed · Cited by 182
The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada
Brisson, M., Van de Velde, N., De Wals, P., & Boily, M.-C. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.04.086 · Cited by 175
Does the arXiv lead to higher citations and reduced publisher downloads for mathematics articles?
Davis, P. M., & Fromerth, M. J. (2007) · Scientometrics · doi:10.1007/s11192-007-1661-8 · Cited by 174
Cost-effectiveness of HPV 16, 18 vaccination in Brazil
Goldie, S. J., Kim, J. J., Kobus, K., Goldhaber-Fiebert, J. D., Salomon, J., O'Shea, M. K. H., Xavier Bosch, F., de Sanjosé, S., & Franco, E. L. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.05.058 · Cited by 167
Kim, J. J., Andres-Beck, B., & Goldie, S. J. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604023 · Cited by 156
Cost-effectiveness of Human Papillomavirus Vaccination in the United States
Chesson, H. W., Ekwueme, D. U., Saraiya, M., & Markowitz, L. E. (2008) · Emerging infectious diseases · doi:10.3201/eid1402.070499 · Cited by 154
Stochastic modeling of citation slips
Simkin, M. V., & Roychowdhury, V. P. (2005) · Scientometrics · doi:10.1007/s11192-005-0028-2 · Cited by 135
Nanda, K., McCrory, D., Er, M., Bastian, L., Hasselblad, V., Hickey, J., & Matchar, D. B. (2001) · Journal of Lower Genital Tract Disease · doi:10.1046/j.1526-0976.2001.51012-12.x · Cited by 129
Estimation of the impact of genital warts on health-related quality of life
Woodhall, S. C., Ramsey, T., Cai, C., Crouch, S., Jit, M., Birks, Y. F., Edmunds, W. J., Newton, R., & Lacey, C. J. (2008) · Sexually Transmitted Infections · doi:10.1136/sti.2007.029512 · Cited by 121
Self-citationKohli, M. A., Ferko, N. C., Martin, A., Franco, E. L., Jenkins, D., Gallivan, S., Sherlaw‐Johnson, C., & Drummond, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603501 · Cited by 113
Nanda, K., McCrory, D., Myers, E., Bastian, L., Hasselblad, V., Hickey, J., & Matchar, D. B. (2001) · Journal of Lower Genital Tract Disease · doi:10.1111/j.1526-0976.2001.51012-12.pp.x · Cited by 104
Open access and openly accessible: a study of scientific publications shared via the internet
Wren, J. D. (2005) · BMJ · doi:10.1136/bmj.38422.611736.e0 · Cited by 98
Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK
Brown, R. E., Breugelmans, J. G., Theodoratou, D., & Bénard, S. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x99972 · Cited by 90
Dasbach, E. J., Insinga, R. P., & Elbasha, E. H. (2008) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2008.01743.x · Cited by 88
Kulasingam, S., Bénard, S., Barnabas, R. V., Largeron, N., & Myers, E. R. (2008) · Cost Effectiveness and Resource Allocation · doi:10.1186/1478-7547-6-4 · Cited by 88
A Catalog of Dermatology Utilities: A Measure of the Burden of Skin Diseases
Chen, S. C., Bayoumi, A. M., Soon, S. L., Aftergut, K., Cruz, P. D., Sexton, S. A., McCall, C. O., & Goldstein, M. K. (2004) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1046/j.1087-0024.2003.09112.x · Cited by 79
Abnormal Outcomes Following Cervical Cancer Screening: Event Duration and Health Utility Loss
Insinga, R. P., Glass, A. G., Myers, E. R., & Rush, B. B. (2007) · Medical Decision Making · doi:10.1177/0272989x07302128 · Cited by 64
Prevalence of human papillomavirus antibodies in young female subjects in England
Jit, M., Vyse, A., Borrow, R., Pebody, R. G., Soldan, K., & Miller, E. J. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603955 · Cited by 63
Self-citationPapillomavirus vaccines in perspective
Kahn, J. A., & Burk, R. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60947-7 · Cited by 57
Open Access does not increase citations for research articles from The Astrophysical JournalPreprint
Kurtz, M. J., & Henneken, E. A. (2007) · arXiv (Cornell University) · doi:10.48550/arxiv.0709.0896 · Cited by 54
Stage-specific treatment costs for cervical cancer in the United Kingdom
Wolstenholme, J. L., & Whynes, D. K. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00232-9 · Cited by 54
The cervical cancer epidemic that screening has prevented in the U.K.
(2004) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000143133.58382.ed · Cited by 28
Martin‐Hirsch, P. L., Rash, B., Martin, A., & Standaert, B. A. (2007) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2007.01261.x · Cited by 25
Copied citations give impact factors a boost
Clarke, T. (2003) · Nature · doi:10.1038/423373a · Cited by 10
Cited by
Surveillance of vaccination coverage among adult populations—United States, 2015.
Williams, W. W., Lu, P.-J., O’Halloran, A., Kim, D. K., Grohskopf, L. A., Pilishvili, T., Skoff, T. H., Nelson, N. P., Harpaz, R., Markowitz, L. E., et al. (2017) · MMWR Surveillance Summaries · doi:10.15585/mmwr.ss6611a1 · Cited by 442
Malagón, T., Drolet, M., Boily, M.-C., Franco, E. L., Jit, M., Brisson, J., & Brisson, M. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70187-1 · Cited by 429
Self-citationLiterature review: The vaccine supply chain
Duijzer, L. E., van Jaarsveld, W., & Dekker, R. (2018) · European Journal of Operational Research · doi:10.1016/j.ejor.2018.01.015 · Cited by 258
Calibrating Models in Economic Evaluation: A Seven-Step Approach
Vanni, T., Karnon, J., Madan, J., White, R. G., Edmunds, W. J., Foss, A. M., & Legood, R. (2011) · PharmacoEconomics · doi:10.2165/11584600-000000000-00000 · Cited by 173
Self-citationVan de Velde, N., Boily, M.-C., Drolet, M., Franco, E. L., Mayrand, M.-H., Kliewer, E. V., Coutlée, F., Laprise, J.-F., Malagón, T., & Brisson, M. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs395 · Cited by 140
Metadata
- Authors
- Jit, M., Choi, Y. H., & Edmunds, W. J.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2008-07-17
- Volume
- 337
- Issue
- jul17 2
- Pages
- a769-a769
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2141226130
- Cited by
- 273
- References
- 44
- FWCI
- 24.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.